On 10 November, EIP Pharma, a clinical-stage pharma company focused on the development of disease-modifying treatments for dementia and neurodegenerative diseases, announced that the final results of its AscenD-LB phase II clinical study of its oral investigational drug neflamapimod, in mild-to-moderate dementia with Lewy bodies were presented at the 14th Clinical Trials in Alzheimer’s Disease (CTAD) conference.
AscenD-LB was a Phase II double-blind, placebo-controlled and 16-week treatment proof-of-concept study evaluating neflamapimod in 91 people with mild-to-moderate dementia with Lewy bodies in the US and the Netherlands. They received either 40 mg neflamapimod capsules or placebo capsules for 16 weeks. The results demonstrated that neflamapimod treatment led to significant improvement relative to placebo in cognition and function, as assessed in a DLB-specific Neuropsychological Test Battery and the Clinical Dementia Rating scale Sum of Boxes (CDR-SB). In addition, significant improvement was observed in motor function, specifically functional mobility, as measured by the Timed Up and Go (TUG) test.
https://www.eippharma.com/news/presentation-at-14th-ctad-conference-november-10-2021/
